Literature DB >> 34144044

COVID-19 vaccination is safe and effective in patients with inflammatory bowel disease: Analysis of a large multi-institutional research network in United States.

Yousaf Bashir Hadi1, Shyam Thakkar1, Sardar Momin Shah-Khan1, William Hutson1, Arif Sarwari2, Shailendra Singh3.   

Abstract

Entities:  

Year:  2021        PMID： 34144044     DOI： 10.1053/j.gastro.2021.06.014

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  23 in total

1.  Impact of BNT162b2 mRNA Vaccination on the Development of Short and Long-Term Vaccine-Related Adverse Events in Inflammatory Bowel Disease: A Multi-Center Prospective Study.

Authors:  Mohammad Shehab; Fatema Alrashed; Israa Abdullah; Ahmad Alfadhli; Hamad Ali; Mohamed Abu-Farha; Arshad Mohamed Channanath; Jehad Ahmed Abubaker; Fahd Al-Mulla
Journal:  Front Med (Lausanne)       Date:  2022-06-08

2.  Spontaneous Myocarditis in Mice Predisposed to Autoimmune Disease: Including Vaccination-Induced Onset.

Authors:  Takuma Hayashi; Motoki Ichikawa; Ikuo Konishi
Journal:  Biomedicines       Date:  2022-06-18

Review 3.  Immunizing the imperfect immune system: Coronavirus disease 2019 vaccination in patients with inborn errors of immunity.

Authors:  Jessica R Durkee-Shock; Michael D Keller
Journal:  Ann Allergy Asthma Immunol       Date:  2022-06-16       Impact factor: 6.248

4.  Effectiveness and Safety of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease.

Authors:  Emily Spiera; Ryan C Ungaro; Asher Kornbluth
Journal:  Gastroenterol Hepatol (N Y)       Date:  2022-03

Review 5.  Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic.

Authors:  Simeng Lin; Louis Hs Lau; Neil Chanchlani; Nicholas A Kennedy; Siew C Ng
Journal:  Gut       Date:  2022-04-27       Impact factor: 31.793

6.  Real-World Use and Adverse Events of SARS-CoV-2 Vaccination in Greek Patients with Inflammatory Bowel Disease.

Authors:  Eleni Orfanoudaki; Eirini Zacharopoulou; Vassiliki Kitsou; Konstantinos Karmiris; Angeliki Theodoropoulou; Gerassimos J Mantzaris; Maria Tzouvala; Spyridon Michopoulos; Evanthia Zampeli; Georgios Michalopoulos; Pantelis Karatzas; Nikos Viazis; Christos Liatsos; Giorgos Bamias; Ioannis E Koutroubakis
Journal:  J Clin Med       Date:  2022-01-27       Impact factor: 4.241

Review 7.  Effectiveness and Durability of COVID-19 Vaccination in 9447 Patients With IBD: A Systematic Review and Meta-Analysis.

Authors:  Anuraag Jena; Deepak James; Anupam K Singh; Usha Dutta; Shaji Sebastian; Vishal Sharma
Journal:  Clin Gastroenterol Hepatol       Date:  2022-02-19       Impact factor: 13.576

8.  Acceptance of COVID-19 Vaccines among Patients with Inflammatory Bowel Disease in Japan.

Authors:  Yu Nishida; Shuhei Hosomi; Yumie Kobayashi; Rieko Nakata; Masaki Ominami; Yuji Nadatani; Shusei Fukunaga; Koji Otani; Fumio Tanaka; Yasuaki Nagami; Koichi Taira; Noriko Kamata; Yasuhiro Fujiwara
Journal:  Healthcare (Basel)       Date:  2021-12-22

9.  Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients.

Authors:  Neil Chanchlani; Simeng Lin; Desmond Chee; Benjamin Hamilton; Rachel Nice; Zehra Arkir; Claire Bewshea; Bessie Cipriano; Lauranne A A P Derikx; Allan Dunlop; Louise Greathead; Rachel L Griffiths; Hajir Ibraheim; Peter Kelleher; Klaartje B Kok; Charlie W Lees; Jonathan MacDonald; Shaji Sebastian; Philip J Smith; Timothy J McDonald; Peter M Irving; Nick Powell; Nicholas A Kennedy; James R Goodhand; Tariq Ahmad
Journal:  J Crohns Colitis       Date:  2022-03-14       Impact factor: 9.071

10.  COVID-19 Vaccine Is Effective in Inflammatory Bowel Disease Patients and Is Not Associated With Disease Exacerbation.

Authors:  Raffi Lev-Tzion; Gili Focht; Rona Lujan; Adi Mendelovici; Chagit Friss; Shira Greenfeld; Revital Kariv; Amir Ben-Tov; Eran Matz; Daniel Nevo; Yuval Barak-Corren; Iris Dotan; Dan Turner
Journal:  Clin Gastroenterol Hepatol       Date:  2021-12-23       Impact factor: 13.576
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.